NCT06899204View on ClinicalTrials.gov

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Not yet recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

September 30, 2026

Conditions
Atopic DermatitisAtopic Dermatitis, UnspecifiedDermatitis, Atopic
Interventions
DRUG

Abrocitinib

Study Drug for Observational Data Collection.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06899204 - Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | Biotech Hunter | Biotech Hunter